TG Therapeutics Inc (TGTX)

Debt-to-equity ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Long-term debt	US$ in thousands	244,158	102,537	101,326	100,118	98,908	97,700	96,503	71,135	71,135	68,947	67,249	66,788	—	—	—	7,716	15,074	22,233	29,201	28,970
Total stockholders’ equity	US$ in thousands	192,157	177,568	160,109	160,502	164,769	40,453	27,433	58,587	100,481	129,035	170,386	237,153	311,517	383,130	445,285	519,350	170,658	194,227	-1,353	38,615
Debt-to-equity ratio		1.27	0.58	0.63	0.62	0.60	2.42	3.52	1.21	0.71	0.53	0.39	0.28	0.00	0.00	0.00	0.01	0.09	0.11	—	0.75

September 30, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $244,158K ÷ $192,157K
= 1.27

The debt-to-equity ratio of TG Therapeutics Inc has shown fluctuations over the historical periods. As of September 30, 2024, the ratio stands at 1.27, indicating that the company relies more on debt financing compared to equity. This represents an increase from the previous quarter's ratio of 0.58.

Looking back, there have been significant variations in the ratio, with peaks observed in the first quarter of 2023 and the second quarter of 2023 at 3.52 and 2.42, respectively. These high ratios suggest higher levels of debt relative to equity during those periods.

It is worth noting that the company's debt-to-equity ratio has been relatively low or even at 0 in some quarters in the past, such as in the last two quarters of 2021 and in the first three quarters of 2020. This indicates a lower reliance on debt financing during those periods.

Overall, the trend in the debt-to-equity ratio highlights the company's changing capital structure and the extent to which it utilizes debt to fund its operations and growth initiatives. Further analysis would be advisable to understand the reasons behind the fluctuations and their potential impact on the company's financial stability and risk profile.